Provided by Tiger Trade Technology Pte. Ltd.

BioRestorative Therapies, Inc.

2.76
+0.02000.73%
Post-market: 2.760.00000.00%16:10 EDT
Volume:27.42K
Turnover:76.25K
Market Cap:3.81M
PE:-0.13
High:2.82
Open:2.82
Low:2.70
Close:2.74
52wk High:34.60
52wk Low:2.61
Shares:1.38M
Float Shares:1.25M
Volume Ratio:0.40
T/O Rate:2.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-21.2000
EPS(LYR):-31.6731
ROE:-241.14%
ROA:-118.81%
PB:1.26
PE(LYR):-0.09

Loading ...

Biorestorative Therapies - Lance Alstodt Resigns as President, CEO, Chairman and All Other Positions Effective July 13, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 17

Biorestorative Therapies - Robert Kristal Resigns as CFO and All Other Positions Effective July 13, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 17

Biorestorative CEO Lance Alstodt, CFO Robert Kristal Resign Effective Immediately

Reuters
·
Jul 17

Biorestorative Completes Phase 2 Manufacturing for Brtx-100 Lumbar Disc Disease Trial Supply

Reuters
·
Jun 25

BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform

GlobeNewswire
·
Jun 25

BioRestorative Therapies files Form 3 for director Jatinder Dhaliwal, reporting no beneficial ownership

Reuters
·
Jun 19

BioRestorative names Zachary Smith VP of biocosmeceuticals division

Reuters
·
Jun 18

BioRestorative Therapies Strengthens Leadership With Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth

THOMSON REUTERS
·
Jun 18

BioRestorative Therapies director Katharyn Field files initial beneficial ownership statement

Reuters
·
Jun 18

BioRestorative adds lender designees Grasso, Field, Dhaliwal to board after three director resignations

Reuters
·
Jun 13

BioRestorative publishes investor presentation on BRTX-100 stem cell therapy for chronic lumbar disc disease

Reuters
·
Jun 02

BioRestorative names Lance Alstodt chairman, CEO and president under new employment deal

Reuters
·
May 30

BioRestorative Therapies shareholder Kaos Capital acquires 4.9% stake

TIPRANKS
·
May 27

Kaos Capital discloses 4.9% stake in BioRestorative Therapies

Reuters
·
May 27

Kaos Capital: Urgently Seeks Meeting With BioRestorative Therapies Board to Discuss Unlocking Shareholder Value

THOMSON REUTERS
·
May 27

Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (Nasdaq: Brtx)

THOMSON REUTERS
·
May 27

BioRestorative Therapies completes Phase 2 dosing of BRTX-100

TIPRANKS
·
May 27

BioRestorative completes Phase 2 dosing of BRTX-100 in chronic lumbar disc disease trial, targets Q2 2027 data

Reuters
·
May 26

BioRestorative Therapies Inc - Topline Phase 2 Data for Brtx-100 Expected in Q2 2027

THOMSON REUTERS
·
May 26

BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data

GlobeNewswire
·
May 26